LONDON, Jan. 07, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the appointment of David Moskowitz … Continue reading “Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations”
‒ The Fund has now committed a total of USD 48 million to eight companies ‒ REPAIR to adjust strategic scope for 2020 ‒ Global call for investment proposals will open during summer … Continue reading “Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines and provides strategic update”
To accelerate development of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – 17 December 2019 – Edinburgh Molecular Imaging Ltd (EMI), a company … Continue reading “Edinburgh Molecular Imaging Closes Financing”
Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces signing of a License and Collaboration Agreement with Novartis. The joint research collaboration … Continue reading “Forendo Pharma signs important License and Collaboration Deal with Leading Pharma Company”
09 December 2019, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics announces today, that its collaborator Dr. Konstantinos Tzelepis, Sir … Continue reading “STORM Therapeutics’ collaborator awarded ASH–BSH Abstract Achievement Award at the 61st ASH Annual Meeting & Exposition”
LOS ANGELES, Dec. 9, 2019 /PRNewswire/ — ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at … Continue reading “ImaginAb Initiates Phase II Clinical Trial at Penn Medicine”
Enzyre, which is developing breakthrough ambulant diagnostic technology for coagulation testing, today announced that it has entered into a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop … Continue reading “Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home”
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience clinical drug development, today announces that it is scheduled to attend and present scientific posters at the … Continue reading “IXICO to Present Abstracts at Upcoming Clinical Trials on Alzheimer’s Disease Congress”
PARIS and NEW YORK, Dec. 2, 2019 /PRNewswire/ — Owkin, which is developing Federated Learning and AI technologies to advance medical research, announces it is teaming up with technology company NVIDIA and King’s College London (KCL) to … Continue reading “Owkin Teams up with NVIDIA and King’s College London to Deliver AI to Hospitals While Protecting Patient Data With Federated Learning”
LANGENFELD, Germany, Nov. 28, 2019 /PRNewswire/ — Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announces expansion of its operations in Southern Europe with the launch of Neuraxpharm … Continue reading “European CNS Specialist Neuraxpharm Expands Southern European Presence with Expansion into Portugal”
Date: November 26, 2019 Location: Copenhagen Martin Bonde, John Haurum and Anders Hinsby join as Entrepreneurs-in-Residence Peter Hirth and Anders Gersel Pedersen join as Advisors Novo Seeds, the early stage … Continue reading “Novo Seeds expands company formation activities at BiOrigin with seasoned entrepreneurs”
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, will announce its final results for the year ended 30 September 2019 on Wednesday, 4 December 2019. … Continue reading “IXICO Notice of Results”
Syncona leads £32.0 million Series B financing of Azeria Therapeutics with a £29.5 million commitment Opportunity to address a significant unmet need in oestrogen receptor positive breast cancer patients in … Continue reading “Azeria Therapeutics announces £32.0 million series B financing”
Industry veterans including Craig Lipset will support Castor’s vision to advance the future of clinical research Amsterdam, Netherlands and Hoboken, New Jersey: November 18, 2019: Castor, a health-tech company that … Continue reading “Castor Establishes Advisory Board of Industry Leaders to Maximize the Impact of its Clinical Data Platform”
Chris Sterling appointed as Non-Executive Director & Radiopharmaceutical drug development expert Dr Daniel Stevens joins as Chief Medical Officer LONDON, UK, 14 November 2019 – Theragnostics, which is developing molecular … Continue reading “Theragnostics strengthens leadership team with two key appointments”
Positive Regulatory Outcome – Enhanced study design “This third quarter of 2019 saw us move steadily towards full recruitment of the NefIgArd study, despite a somewhat slower pace during the … Continue reading “Calliditas Interim Report Q3, 2019”
In Phase 2b development for the treatment of life-threatening fungal infections First antifungal agent to receive Breakthrough Therapy designation MANCHESTER, UK / VIENNA, Austria – November 11, 2019 – F2G Ltd, … Continue reading “F2G Receives US FDA Breakthrough Therapy Designation for Olorofim”
CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of … Continue reading “Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor”
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present scientific posters at the following conferences in … Continue reading “IXICO to Present Abstracts at Upcoming Huntington’s Disease and Ataxia Conferences”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com